Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
about
Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyTargeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
P2860
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and Safety of Bevaciz ...... OSiA Single-Arm Phase 3B Study
@en
Efficacy and Safety of Bevaciz ...... SiA Single-Arm Phase 3B Study.
@nl
type
label
Efficacy and Safety of Bevaciz ...... OSiA Single-Arm Phase 3B Study
@en
Efficacy and Safety of Bevaciz ...... SiA Single-Arm Phase 3B Study.
@nl
prefLabel
Efficacy and Safety of Bevaciz ...... OSiA Single-Arm Phase 3B Study
@en
Efficacy and Safety of Bevaciz ...... SiA Single-Arm Phase 3B Study.
@nl
P2093
P2860
P1476
Efficacy and Safety of Bevaciz ...... OSiA Single-Arm Phase 3B Study
@en
P2093
Amit M Oza
Andrea DeCensi
Angiolo Gadducci
Antonio González-Martín
Aristotelis Bamias
Cesar Mendiola
Claudio Zamagni
Ewa Chmielowska
Frédéric Selle
Irina Davidenko
P2860
P356
10.1097/IGC.0000000000000836
P577
2016-10-04T00:00:00Z